Analyst: This Pharma Stock Could Triple

The brokerage firm also initiated coverage with an "outperform" rating

Dec 7, 2018 at 10:35 AM
facebook twitter linkedin


RBC initiated coverage on Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) with an "outperform" rating and $23 price target -- a 245% premium to last night's close. The analyst in coverage waxed optimistic over the long-term upside potential of the drugmaker's lead drug lenabasum, which is currently undergoing trials in patients with cystic fibrosis and systemic sclerosis.

In response, CRBP is trading up 5.8% at $7.05. The shares shot nearly 54% higher back on Sept. 20, on the back of a well-received licensing deal, but have since been stuck beneath a trendline connecting lower highs from early October. Today's pop has the shares aiming for a close in positive year-to-date territory, having entered 2018 trading at $7.10.

crbp stock daily price chart on dec 7

Analysts have remained upbeat on the shares, with 100% of those in coverage maintaining a "buy" or better rating. Plus, the average 12-month price target sits all the way up at $23.33.

Short sellers, on the other hand, have been actively targeting CRBP stock. Short interest on the pharma name is up almost 82% since the start of the year, to 14.12 million shares, and hit a record high 14.53 million shares in the Nov. 1 reporting period. The current number of shorted shares accounts for 26.3% of the equity's available float, or 15 times the average daily pace of trading.
 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners